Do we have enough evidence to implement particle therapy as standard treatment in lung cancer? A systematic literature review

Oncologist

Volumn 15, Issue 1, 2010, Pages 93-103

  Pijls Johannesma, Madelon ^a   Grutters, Janneke P C ^a,b   Verhaegen, Frank ^a,c   Lambin, Philippe ^a   De Ruysscher, Dirk ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Carbon ion; Hadron; Heavier charged particles; Lung cancer; Proton; Radiotherapy

Indexed keywords

CANCER CONTROL; CANCER THERAPY; CAUSE SPECIFIC SURVIVAL; CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; DERMATITIS; DISEASE SEVERITY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; ION THERAPY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; OVERALL SURVIVAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROTON THERAPY; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA; REVIEW; STEREOTACTIC TREATMENT; SYSTEMATIC REVIEW; TREATMENT PLANNING;

CARBON RADIOISOTOPES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DOSE FRACTIONATION; HUMANS; LUNG NEOPLASMS; PROTONS; QUALITY OF LIFE; RADIOTHERAPY; RADIOTHERAPY DOSAGE;

EID: 75649148800     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0116     Document Type: Review

References (66)

1. Shibuya K, Mathers CD, Boschi-Pinto C et al. Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer 2002;2:37.
2. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43- 66.
3. Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-592.
4. Kim YS, Yoon SM, Choi EK et al. Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for stage IIIB non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2005;62:76-81.
5. Farray D, Mirkovic N, Albain KS. Multimodality therapy for stage III nonsmall-cell lung cancer. J Clin Oncol 2005;23:3257-3269.
6. Martel MK, Ten Haken RK, Hazuka MB et al. Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer 1999;24:31-37.
7. De Jaeger K, Seppenwoolde Y, Boersma LJ et al. Pulmonary function following high-dose radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2003;55:1331-1340.
8. Bush DA, Slater JD, Bonnet R et al. Proton-beam radiotherapy for earlystage lung cancer. Chest 1999;116:1313-1319.
9. Shioyama Y, Tokuuye K, Okumura T et al. Clinical evaluation of proton radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2003;56:7-13.
10. Koto M, Miyamoto T, Yamamoto N et al. Local control and recurrence of stage I non-small cell lung cancer after carbon ion radiotherapy. Radiother Oncol 2004;71:147-156.
11. Miyamoto T, Yamamoto N, Nishimura H et al. Carbon ion radiotherapy for stage I non-small cell lung cancer. Radiother Oncol 2003;66:127-140.
12. Nishimura H, Miyamoto T, Yamamoto N et al. Radiographic pulmonary and pleural changes after carbon ion irradiation. Int J Radiat Oncol Biol Phys 2003;55:861- 866.
13. Krengli M, Hug EB, Adams JA et al. Proton radiation therapy for retinoblastoma: Comparison of various intraocular tumor locations and beam arrangements. Int J Radiat Oncol Biol Phys 2005;61:583-593.
14. St Clair WH, Adams JA, Bues M et al. Advantage of protons compared to conventional x-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. Int J Radiat Oncol Biol Phys 2004;58:727-734.
15. Weber DC, Trofimov AV, Delaney TF et al. A treatment planning comparison of intensity modulated photon and proton therapy for paraspinal sarcomas. Int J Radiat Oncol Biol Phys 2004;58:1596 -1606.
16. Baumert BG, Lomax AJ, Miltchev V et al. A comparison of dose distributions of proton and photon beams in stereotactic conformal radiotherapy of brain lesions. Int J Radiat Oncol Biol Phys 2001;49:1439 -1449.
17. Zurlo A, Lomax A, Hoess A et al. The role of proton therapy in the treatment of large irradiation volumes: A comparative planning study of pancreatic and biliary tumors. Int J Radiat Oncol Biol Phys 2000;48:277-288.
18. Miralbell R, Crowell C, Suit HD. Potential improvement of three dimension treatment planning and proton therapy in the outcome of maxillary sinus cancer. Int J Radiat Oncol Biol Phys 1992;22:305-310.
19. Miralbell R, Lomax A, Russo M. Potential role of proton therapy in the treatment of pediatric medulloblastoma/primitive neuro-ectodermal tu-mors: Spinal theca irradiation. Int J Radiat Oncol Biol Phys 1997;38:805-811.
20. Cozzi L, Fogliata A, LomaxAet al.Atreatment planning comparison of 3D conformal therapy, intensity modulated photon therapy and proton therapy for treatment of advanced head and neck tumours. Radiother Oncol 2001; 61:287-297.
21. Lee CH, Tait D, Nahum AE et al. Comparison of proton therapy and conformal x-ray therapy in non-small cell lung cancer (NSCLC). Br J Radiol 1999;72:1078 -1084.
22. Fogliata A, Bolsi A, Cozzi L. Critical appraisal of treatment techniques based on conventional photon beams, intensity modulated photon beams and proton beams for therapy of intact breast. Radiother Oncol 2002;62: 137-145.
23. Isacsson U, Montelius A, Jung B et al. Comparative treatment planning between proton and x-ray therapy in locally advanced rectal cancer. Radiother Oncol 1996;41:263-272.
24. Isacsson U, Hagberg H, Johansson KA et al. Potential advantages of protons over conventional radiation beams for paraspinal tumours. Radiother Oncol 1997;45:63-70.
25. Tsujii H, Mizoe J, Kamada T et al. Clinical results of carbon ion radiotherapy at NIRS. J Radiat Res (Tokyo) 2007;48(suppl A):A1-A13.
26. Lodge M, Pijls-Johannesma M, Stirk L et al. A systematic literature review of the clinical and cost-effectiveness of hadron therapy in cancer. Radiother Oncol 2007;83:110 -122.
27. Pijls-Johannesma M, Grutters JP, Lambin P et al. Particle therapy in lung cancer: Where do we stand? Cancer Treat Rev 2008;34:259 -267.
28. Pijls-Johannesma M, Pommier P, Lievens Y. Cost-effectiveness of particle therapy: Current evidence and future needs. Radiother Oncol 2008;89:127-134.
29. Bush DA, Slater JD, Shin BB et al. Hypofractionated proton beam radiotherapy for stage I lung cancer. Chest 2004;126:1198 -1203.
30. Hata M, Tokuuye K, Kagei K et al. Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: Preliminary results of a phase I/II clinical study. Int J Radiat Oncol Biol Phys 2007;68:786 -793.
31. Miyamoto T, Baba M, YamamotoNet al. Curative treatment of stage I nonsmall-cell lung cancer with carbon ion beams using a hypofractionated regimen. Int J Radiat Oncol Biol Phys 2007;67:750 -758.
32. Nihei K, Ogino T, Ishikura S et al. High-dose proton beam therapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006;65:107-111.
33. Sugane T, Baba M, Imai R et al. Carbon ion radiotherapy for elderly patients 80 years and older with stage I non-small cell lung cancer. Lung Cancer 2009;64:45-50.
34. Brower V. Carbon ion therapy to debut in Europe. J Natl Cancer Inst 2009; 101:74 -76.
35. Greco C, Wolden S. Current status of radiotherapy with proton and light ion beams. Cancer 2007;109:1227-1238.
36. Jäkel O, Karger CP, Debus J. The future of heavy ion radiotherapy. Med Phys 2008;35:5653-5663.
37. Jalali R. Particle therapy in clinical practice: Is there enough evidence to justify the current surge in interest? J Cancer Res Ther 2008;4:54 -56.
38. Jones B. The case for particle therapy. Br J Radiol 2006;79:24 -31.
39. Miyamoto T, Baba M, Sugane T et al. Carbon ion radiotherapy for stage I non-small cell lung cancer using a regimen of four fractions during 1 week. J Thorac Oncol 2007;2:916 -926.
40. Bush DA, Hillebrand DJ, Slater JM et al. High-dose proton beam radiotherapy of hepatocellular carcinoma: Preliminary results of a phase II trial. Gastroenterology 2004;127:S189 -S193.
41. Chang JY, Liu HH, Komaki R. Intensity modulated radiation therapy and proton radiotherapy for non-small cell lung cancer. Curr Oncol Rep 2005; 7:255-259.
42. Orecchia R, Zurlo A, Loasses A et al. Particle beam therapy (hadrontherapy): Basis for interest and clinical experience. Eur J Cancer 1998;34: 459-468.
43. Bentzen SM. Randomized controlled trials in health technology assessment: Overkill or overdue? Radiother Oncol 2008;86:142-147.
44. Sirzén F, Kjellén E, Sörenson S et al. A systematic overview of radiation therapy effects in non-small cell lung cancer. Acta Oncol 2003;42:493-515.
45. Jeremic B, Classen J, Bamberg M. Radiotherapy alone in technically operable, medically inoperable, early-stage (I/II) non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002;54:119 -130.
46. Qiao X, Tullgren O, Lax I et al. The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer 2003;41:1-11.
47. Fakiris AJ, McGarry RC, Yiannoutsos CT et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: Four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 2009;75:677-682.
48. Timmerman R, Papiez L, McGarry R et al. Extracranial stereotactic radioablation: Results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003;124:1946 -1955.
49. Uematsu M, Shioda A, Suda A et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: A 5-year experience. Int J Radiat Oncol Biol Phys 2001;51:666-670.
50. Nyman J, Johansson KA, Hultén U. Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer - mature results for medically inoperable patients. Lung Cancer 2006;51:97-103.
51. Onishi H, Araki T, Shirato H et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: Clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004;101:1623-1631.
52. Timmerman R, McGarry R, Yiannoutsos C et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006;24:4833- 4839.
53. De Ruysscher D, Pijls-Johannesma M, Bentzen SM et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 2006;24:1057-1063.
54. Pijls-Johannesma MC, De Ruysscher D, Lambin P et al. Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev 2005;(1):CD004700.
55. Onishi H, Shirato H, Nagata Y et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: Updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007;2(suppl 3):S94 -S100.
56. Zimmermann FB, Geinitz H, Schill S et al. Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC). Acta Oncol 2006;45:796-801.
57. Goitein M, Jermann M. The relative costs of proton and x-ray radiation therapy. Clin Oncol (R Coll Radiol) 2003;15:S37-S50.
58. Perrier L, Combs S, Auberger T et al. A decision-making tool for a costly innovative technology: The case of carbon ion radiotherapy. J Econ Med 2007;25:367-380.
59. Komaki R, Sejpal S, Wei X et al. Reduction of Bone Marrow Suppression for Patients With Stage III NSCLC Treated by Proton and Chemotherapy Compared With IMRT and Chemotherapy. PTCOG 47, Jacksonville, Florida, 2008:14(O10). Available at http://ptcog.web.psi.ch/PTCOG47/ presentations/4-Meeting-Thursday/Session-2/ abstr-komaki.pdf.
60. Sejpal S, Komaki R, Wei X et al. Does Proton Beam Radiotherapy (PBT) Reduce Treatment Related Pneumonitis (TRP) Compared to Intensity Modulated Radiation Therapy (IMRT) in Patients with Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Concurrent Chemotherapy? PTCOG 47, Jacksonville, Florida, 2008:22(O17). Available at http://ptcog.web.psi.ch/PTCOG47/ presentations/5-Meeting-Friday/Session- 3/abstr-sejpal.pdf.
61. Brada M, Pijls-Johannesma M, De Ruysscher D. Current clinical evidence for proton therapy. Cancer J 2009;15:319 -324.
62. Bush DA, Slater JD, Garberoglio C et al. A technique of partial breast irradiation utilizing proton beam radiotherapy: Comparison with conformal xray therapy. Cancer J 2007;13:114 -118.
63. Engelsman M, Rietzel E, Kooy HM. Four-dimensional proton treatment planning for lung tumors. Int J Radiat Oncol Biol Phys 2006;64:1589-1595.
64. Kang Y, Zhang X, Chang JY et al. 4D Proton treatment planning strategy for mobile lung tumors. Int J Radiat Oncol Biol Phys 2007;67:906 -914.
65. Mori S, Endo M, Komatsu S et al. Four-dimensional measurement of lung tumor displacement using 256-multi-slice CT-scanner. Lung Cancer 2007; 56:59-67.
66. Glimelius B, Montelius A. Proton beam therapy: Do we need the randomised trials and can we do them? Radiother Oncol 2007;83:105-109.